alarming rise in antibiotic resistance<\/a>.<\/p>\nIts precision and ability to combat biofilm-associated infections make it a promising alternative to antibiotics, particularly for multidrug-resistant infections.<\/p>\n
A breakthrough in the fight against AMR<\/h3>\n
The patient was treated by Qeen Biotechnologies and received customised bacteriophage therapy under the care of Dr Stephen Vaughan.<\/p>\n
This precision treatment was designed to tackle drug-resistant pathogens that often render traditional antibiotics ineffective.<\/p>\n
The economic and clinical implications of this success are immense, particularly in Canada, where healthcare providers frequently grapple with limited treatment options for AMR infections.<\/p>\n
Traditional therapies for PJIs often involve prolonged antibiotic regimens and costly two-stage revision surgeries, which can exceed $50,000 per procedure.<\/p>\n
These methods also come with significant physical and emotional burdens for patients, including the possibility of amputation or even death when therapies fail.<\/p>\n
Phage therapy, by contrast, offers a targeted approach that minimises the need for extended hospital stays and eliminates the reliance on exorbitantly priced antibiotics sourced from abroad.<\/p>\n
This innovation not only enhances patient outcomes but also presents a sustainable model for healthcare systems managing the increasing prevalence of AMR infections.<\/p>\n
Dt Vaughan added: \u201cInstead of unlocking new research doors, we just kicked down the door. Through a tremendous team effort, including with Dr Tawil, we have been able to offer our patient an experimental treatment that previously seemed like science fiction.<\/p>\n
\u201cBy using phage, we performed groundbreaking research that opens a new therapeutic avenue for Canadian patients with severe infections, giving hope to the most desperate.\u201d<\/p>\n
A call for policy support in Canada<\/h3>\n
Despite its success, bacteriophage therapy faces hurdles in adoption due to the lack of reimbursement policies for the costs associated with phage manufacturing and delivery.<\/p>\n
Qeen Biotechnologies has called on the Canadian government to address these gaps, emphasising the urgent need for regulatory frameworks that facilitate broader access to these life-saving treatments.<\/p>\n
This milestone underscores the transformative potential of bacteriophage therapy in addressing one of the greatest challenges of modern medicine: antimicrobial resistance.<\/p>\n
As global healthcare systems contend with rising infection rates and limited treatment options, bacteriophage therapy emerges as a beacon of hope. Its ability to improve patient outcomes while offering significant economic advantages positions it as a sustainable solution for the future.<\/p>\n","protected":false},"excerpt":{"rendered":"
Qeen Biotechnologies has provided bacteriophage therapy to treat a periprosthetic joint infection caused by an AMR pathogen. Find out more.<\/p>\n","protected":false},"author":15,"featured_media":54058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[10551],"tags":[24363,24638],"acf":[],"yoast_head":"\n
Bacteriophage therapy offers hope for drug-resistant infections<\/title>\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n\n\n\t\n\t\n\t\n